New drug tested for Tough-to-Treat blood cancers
NCT ID NCT04874480
Summary
This is an early-stage study to find the safest dose of a new drug called tegavivint for adults with leukemia that has come back or stopped responding to standard treatments. The drug aims to block cancer cell growth, and researchers are testing it alone and with another drug, decitabine. The main goal is to understand the side effects and determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.